In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas

Bebear, Cécile; Renaudin, H.; Schaeverbeke, Thierry; Leblanc, F.; Bébéar, Christiane

doi:10.1093/jac/43.5.711

Cited by 68 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, some laboratories prefer to test a frozen stock culture that was serially diluted previously to determine the number of viable cells and then dilute it to an inoculum containing 10 4 to 10 5 colorchanging units/ml for use directly after a 2-h prewarming period (435,436). SP4 medium and Hayflick's modified medium (pH 7.4 to 7.6) have been used for determining MICs for M. pneumoniae, with similar results (35,434,435). MIC test mixtures should be incubated at 37°C.…”

Section: Antimicrobial Susceptibility Profilesmentioning

confidence: 99%

Mycoplasma pneumoniaeand Its Role as a Human Pathogen

2004

View full text Add to dashboard Cite

Mycoplasma pneumoniae is a unique bacterium that does not always receive the attention it merits considering the number of illnesses it causes and the degree of morbidity associated with it in both children and adults. Serious infections requiring hospitalization, while rare, occur in both adults and children and may involve multiple organ systems. The severity of disease appears to be related to the degree to which the host immune response reacts to the infection. Extrapulmonary complications involving all of the major organ systems can occur in association with M. pneumoniae infection as a result of direct invasion and/or autoimmune response. The extrapulmonary manifestations are sometimes of greater severity and clinical importance than the primary respiratory infection. Evidence for this organism's contributory role in chronic lung conditions such as asthma is accumulating. Effective management of M. pneumoniae infections can usually be achieved with macrolides, tetracyclines, or fluoroquinolones. As more is learned about the pathogenesis and immune response elicited by M. pneumoniae, improvement in methods for diagnosis and prevention of disease due to this organism may occur

show abstract

Section: Antimicrobial Susceptibility Profilesmentioning

confidence: 99%

Mycoplasma pneumoniaeand Its Role as a Human Pathogen

2004

View full text Add to dashboard Cite

show abstract

“…Compared to ciprofloxacin, moxifloxacin exerts stronger activity against most grampositive organisms and mycobacteria and some nonfermenting bacteria, anaerobes, and chlamydia as well as mycoplasma, while the MICs of moxifloxacin for Enterobacteriaceae and Pseudomonas aeruginosa are usually higher (3,4,8,21,31). Moxifloxacin shows improved activity against topoisomerase IV, which is encoded by the parC and parE genes.…”

mentioning

confidence: 99%

Susceptibilities of Campylobacter jejuni Isolates from Germany to Ciprofloxacin, Moxifloxacin, Erythromycin, Clindamycin, and Tetracycline

Wagner

Jabbusch

Eisenblätter

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

To elucidate Campylobacter jejuni resistance to antibiotics in Germany, MICs of ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline were determined (using agar dilution) for 144 clinical isolates. The data indicate a considerable ciprofloxacin resistance (45.1%) without a clonal relationship of the strains and a greater in vitro activity of moxifloxacin, erythromycin, and clindamycin.

show abstract

“…Moxifloxacin is a new fluoroquinolone compound which has been reported to be more effective than ofloxacin and ciprofloxacin against a wide range of pathogens, including Streptococcus pneumoniae, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila (2,3,(13)(14)(15). The intracellular pharmacokinetic properties of moxifloxacin are improved compared to those of the oldest fluoroquinolone compounds (10).…”

mentioning

confidence: 99%